Drug-testing lab sues standards group over criticism of its methods
16 August 2026 · filed under aa0244b18545
Bulletin
A drug-testing laboratory that previously drew scrutiny from regulators over impurities detected in widely used medicines has filed suit against U.S. Pharmacopeia, the nonprofit that develops quality standards for pharmaceutical products. According to STAT News, the lab accuses USP of making false and misleading statements about its testing methods.
The filing, reported August 14, does not appear in the available material with full detail on the specific remarks at issue or the venue in which the suit was brought. STAT News, which has covered the laboratory’s earlier disputes with regulators over impurity findings, frames the new action as an escalation of an ongoing controversy over how the lab’s methods measure up against accepted pharmacopeial standards.
USP’s standards inform testing protocols used across the pharmaceutical supply chain, including assessments of drug purity and potency that regulators and manufacturers rely upon. A public dispute between a testing lab and the body that sets those benchmarks bears on confidence in the data underlying both human review and automated quality systems in pharmaceutical manufacturing.
No response from USP is included in the cited summary. STAT News indicates the case remains active. Further details, including the specific claims in the complaint and any reply from USP, were not available in the material reviewed for this bulletin.